Back to Search
Start Over
New treatments for methicillin-resistant Staphylococcus aureus
- Source :
- Current Opinion in Critical Care. 15:403-412
- Publication Year :
- 2009
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2009.
-
Abstract
- Purpose of review Methicillin-resistant Staphylococcus aureus (MRSA) is a dynamic pathogen. Rates of MRSA are increasing worldwide. In some centers, MRSA is becoming less susceptible to vancomycin, and these strains have been associated with worse clinical outcomes. Intermediate or fully resistant vancomycin strains of MRSA have emerged clinically, whereas MRSA acquired in the community has become epidemic. The purpose of this manuscript is to provide clinicians with an evidence-based review on new treatments for MRSA. Recent findings Linezolid, daptomycin and tigecycline have been approved during the last decade to treat infections due to MRSA. Although these agents are extremely valuable in the fight against MRSA, each one has limitations. New lypoglycopeptides (telavancin, dalbavancin and oritavancin) are in advanced phase of clinical development. Similarly, new broad-spectrum cephalosporins active against MRSA (e.g. ceftobiprole and ceftaroline) and a new dihydrofolate reductase inhibitor (iclaprim) are in or have completed phase 3 studies. Summary Here, we review the most relevant information on new drugs to treat MRSA. New studies with available agents and upcoming studies with investigational drugs will help to better understand the role of each compound in the treatment of patients infected with MRSA and assist the clinician in keeping pace with this challenging pathogen.
- Subjects :
- Methicillin-Resistant Staphylococcus aureus
medicine.medical_specialty
Ceftobiprole
Minocycline
Tigecycline
Critical Care and Intensive Care Medicine
medicine.disease_cause
chemistry.chemical_compound
Telavancin
Daptomycin
Streptococcal Infections
Acetamides
medicine
Humans
Intensive care medicine
Oxazolidinones
Clinical Trials as Topic
Evidence-Based Medicine
business.industry
Oritavancin
Glycopeptides
Linezolid
Dalbavancin
biochemical phenomena, metabolism, and nutrition
bacterial infections and mycoses
Methicillin-resistant Staphylococcus aureus
Anti-Bacterial Agents
Cephalosporins
Pyrimidines
chemistry
Iclaprim
business
medicine.drug
Subjects
Details
- ISSN :
- 10705295
- Volume :
- 15
- Database :
- OpenAIRE
- Journal :
- Current Opinion in Critical Care
- Accession number :
- edsair.doi.dedup.....fb9886b7c7504eff68f27e1691188707